Additive solution-7 reduces the red blood cell cold storage lesion
Additive solution-7 reduces the red blood cell cold storage lesion
复制标题
DOI：
10.1111/trf.12867
复制
发表时间：
2015-03-01
期刊：
影响因子：
2.9
通讯作者：
Zia, Majid
中科院分区：
文献类型：
--
作者：
Cancelas, Jose A.;Dumont, Larry J.;Zia, Majid
背景长期储存的红细胞（RBC）的输注与体内红细胞回收率下降、红细胞分解产物的输送以及发病率和死亡率增加有关。减轻这种红细胞储存病变的负担是输血医学的主要挑战。 Additive Solution-7 (AS-7) 是一种新型红细胞储存溶液，旨在通过提供磷酸盐和增加缓冲能力来改善红细胞代谢。研究设计和方法在一项前瞻性、随机、三中心试验中测量了 AS-7 中的储存质量，使用来自健康人类受试者的全血单位，这些受试者的红细胞在 AS-7 中储存长达 56 天 (n=120) 或在对照溶液 AS-1 (n=60) 中储存 42 天。 结果溶血与保存在 AS-1 中的红细胞相比，保存在 AS-7 中 42 和 56 天的红细胞中含蛋白质微泡的脱落显着减少。储存在 AS-7 中的红细胞的自体体内回收率在 42 天 (n=27) 时为 885%，在 56 天 (n=27) 时为 82 +/- 3%，超过了目前使用的溶液中储存的红细胞的回收率。 结论 增加红细胞储存系统的磷酸盐、pH 范围和缓冲容量，使红细胞比目前批准的储存系统储存得更好、更长时间。 AS-7 可改善长期储存损伤，从而显着提高体外和体内的活力。
BackgroundTransfusion of long-stored red blood cells (RBCs) is associated with decreased in vivo RBC recovery, delivery of RBC breakdown products, and increased morbidity and mortality. Reducing the burden of this RBC storage lesion is a major challenge in transfusion medicine. Additive solution-7 (AS-7) is a new RBC storage solution designed to improve RBC metabolism by providing phosphate and increasing buffering capacity.Study Design and MethodsStorage quality in AS-7 was measured in a prospective, randomized, three-center trial using units of whole blood from healthy human subjects whose RBCs were stored for up to 56 days in AS-7 (n=120) or for 42 days in the control solution AS-1 (n=60).ResultsHemolysis and shedding of protein-containing microvesicles were significantly reduced in RBCs stored in AS-7 for 42 and 56 days compared with RBCs stored in AS-1. Autologous in vivo recoveries of RBCs stored in AS-7 was 885% at 42 days (n=27) and 82 +/- 3% at 56 days (n=27), exceeding recoveries of RBCs stored in currently used solutions.ConclusionIncreasing the phosphate, pH range, and buffer capacity of a RBC storage system allowed RBCs to be stored better and longer than currently approved storage systems. AS-7 ameliorates the long-term storage lesion resulting in significantly increased viability in vitro and in vivo.